<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C5B309C9-EB0E-4A0A-8060-FA4118AC12AA"><gtr:id>C5B309C9-EB0E-4A0A-8060-FA4118AC12AA</gtr:id><gtr:name>MGB Biopharma Ltd, Glasgow</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/16819474-44DB-40A9-B322-5977D817BF38"><gtr:id>16819474-44DB-40A9-B322-5977D817BF38</gtr:id><gtr:name>Reneuron</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5C79EA54-3195-4792-8B31-9C453EE89F8D"><gtr:id>5C79EA54-3195-4792-8B31-9C453EE89F8D</gtr:id><gtr:name>SB Drug Discovery</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/450A4730-D29D-4D80-9549-CFE053AC2C00"><gtr:id>450A4730-D29D-4D80-9549-CFE053AC2C00</gtr:id><gtr:name>BioGelX</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C5B309C9-EB0E-4A0A-8060-FA4118AC12AA"><gtr:id>C5B309C9-EB0E-4A0A-8060-FA4118AC12AA</gtr:id><gtr:name>MGB Biopharma Ltd, Glasgow</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6711BFCB-ACD5-4149-9C97-283269DF2778"><gtr:id>6711BFCB-ACD5-4149-9C97-283269DF2778</gtr:id><gtr:name>Mayo Clinic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F724BB81-CAD8-43A7-B2C0-394CD9DE4639"><gtr:id>F724BB81-CAD8-43A7-B2C0-394CD9DE4639</gtr:id><gtr:name>University of California, San Diego</gtr:name><gtr:address><gtr:line1>9500 Gilman Drive</gtr:line1><gtr:line4>La Jolla</gtr:line4><gtr:line5>CA 92093</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/16819474-44DB-40A9-B322-5977D817BF38"><gtr:id>16819474-44DB-40A9-B322-5977D817BF38</gtr:id><gtr:name>Reneuron</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5C79EA54-3195-4792-8B31-9C453EE89F8D"><gtr:id>5C79EA54-3195-4792-8B31-9C453EE89F8D</gtr:id><gtr:name>SB Drug Discovery</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/450A4730-D29D-4D80-9549-CFE053AC2C00"><gtr:id>450A4730-D29D-4D80-9549-CFE053AC2C00</gtr:id><gtr:name>BioGelX</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8ED72725-BEBF-45B9-A9D3-8D9798C80F92"><gtr:id>8ED72725-BEBF-45B9-A9D3-8D9798C80F92</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Winn</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12023"><gtr:id>1031968E-A2CD-4612-9526-44316A73460B</gtr:id><gtr:title>Confidence in Concept 2012 - University of Strathclyde</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12023</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>300000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biogelx</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Research collaboration: Carswell</gtr:description><gtr:id>9E934AF7-ABF1-4079-8FB2-59E13762BE11</gtr:id><gtr:impact>Data is being generated of benefit to all 3 parties</gtr:impact><gtr:outcomeId>mCj9agQ6QrG-1</gtr:outcomeId><gtr:partnerContribution>Contribution of materials</gtr:partnerContribution><gtr:piContribution>Collaboration to demonstrate in vivo compatibility of BioGelX scaffolds with ReNeuron stem cells</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Reneuron</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Research collaboration: Carswell</gtr:description><gtr:id>B3CE9607-E009-453D-95F0-820C0D571FEE</gtr:id><gtr:impact>Data is being generated of benefit to all 3 parties</gtr:impact><gtr:outcomeId>mCj9agQ6QrG-2</gtr:outcomeId><gtr:partnerContribution>Contribution of materials</gtr:partnerContribution><gtr:piContribution>Collaboration to demonstrate in vivo compatibility of BioGelX scaffolds with ReNeuron stem cells</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mayo Clinic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Research collaboration: Mackay</gtr:description><gtr:id>0146D6A8-182E-4957-B3E8-A83BD9B65B09</gtr:id><gtr:impact>Data being generated that will add to pre-clinical package for licensing or investment</gtr:impact><gtr:outcomeId>CaRV8FjrHzq-2</gtr:outcomeId><gtr:partnerContribution>Provision of in vivo models</gtr:partnerContribution><gtr:piContribution>First-in-class IKKalpha inhibitors provided to UCSD for in vivo studies in prostate cancer and to Mayo Clinic for in vivo studies in pancreatic cancer.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SB Drug Discovery</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Research collaboration: Pickard</gtr:description><gtr:id>9D353865-2815-4962-AEC5-F1BB1FD6E96E</gtr:id><gtr:impact>Data being generated</gtr:impact><gtr:outcomeId>eGjR6UV44i6-1</gtr:outcomeId><gtr:partnerContribution>Inflammatory disease assay development expertise</gtr:partnerContribution><gtr:piContribution>Development of novel in vitro genetic screening approach for identifying new targets in inflammatory disease.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Diego (UCSD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Research collaboration: Mackay</gtr:description><gtr:id>200B4DE0-E1D2-4867-821A-42D74C4E2DC3</gtr:id><gtr:impact>Data being generated that will add to pre-clinical package for licensing or investment</gtr:impact><gtr:outcomeId>CaRV8FjrHzq-1</gtr:outcomeId><gtr:partnerContribution>Provision of in vivo models</gtr:partnerContribution><gtr:piContribution>First-in-class IKKalpha inhibitors provided to UCSD for in vivo studies in prostate cancer and to Mayo Clinic for in vivo studies in pancreatic cancer.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MGB Biopharma Ltd, Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Research collaboration: Tucker</gtr:description><gtr:id>7BD16F28-CFC9-4403-826A-0DCA09DF4824</gtr:id><gtr:impact>Demonstration of Gram negative activity for compounds</gtr:impact><gtr:outcomeId>pcR9MtCzMSz-1</gtr:outcomeId><gtr:partnerContribution>Provision of compounds</gtr:partnerContribution><gtr:piContribution>Data generated contributing to pre-clinical data package</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>175000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK project grant</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20199</gtr:fundingRef><gtr:id>AC0D7D37-BC67-4BA3-AEE8-30E00DCC7B50</gtr:id><gtr:outcomeId>58ac2100c52cd1.19682284</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SMART grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>68D0E3EB-3EC1-4EAC-A89F-EFED6D7CE265</gtr:id><gtr:outcomeId>58ac228fd7c086.35138646</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Regional Development Fund (ERDF)</gtr:department><gtr:description>SIPBS KE Hub</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>82C93028-138E-48E3-98D1-4CB87F2AD90A</gtr:id><gtr:outcomeId>YyL6LhDZrNe</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SULSA-MSD</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>8861EB86-735E-4AE1-AD4A-0C0FEC8EBB8B</gtr:id><gtr:outcomeId>ZQWqfCWQMK2</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development Pathway Funding Scheme</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C038E005-0EB3-4FC3-9ECD-E1A0E8BE7D6A</gtr:id><gtr:outcomeId>57125aca818840.73218175</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MSD / SULSA</gtr:description><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>961E3F4A-7205-44F7-B93A-2544B87310D4</gtr:id><gtr:outcomeId>57125bd3eb6003.62477564</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>116784</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chief Scientist's Office grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:fundingRef>160125</gtr:fundingRef><gtr:id>7B885BBA-DCDD-442C-A2A1-BCCE8259EB08</gtr:id><gtr:outcomeId>58ac21c4a29d06.79763621</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Drug Discovery Project Award</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>A18474</gtr:fundingRef><gtr:id>6590AC5A-A65F-4277-B8E4-9DC2D9E8EC0A</gtr:id><gtr:outcomeId>57125a097b3845.81154142</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>249289</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer UK Project Grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:fundingRef>PG12-27</gtr:fundingRef><gtr:id>F577254D-A425-489D-A565-E708EFD555F1</gtr:id><gtr:outcomeId>571a23966490e2.78221387</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>369782</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Responsive mode, Panel D, The differing biological fates of DNA minor groove-binding (MGB) antibiotics in Gram-negative and Gram-Positive bacteria.</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K019600/1</gtr:fundingRef><gtr:id>8F2D8012-6336-41C3-87B2-6080CB7BDC6F</gtr:id><gtr:outcomeId>5712592eb41160.13042989</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9E36A4BF-7743-4159-A4DF-90C32E2CFA53</gtr:id><gtr:title>Immunomodulatory role of proteinase-activated receptor-2.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3e0cf05d42ddc60f2294d6f218ba72c"><gtr:id>f3e0cf05d42ddc60f2294d6f218ba72c</gtr:id><gtr:otherNames>Crilly A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>56e12f7f57ffc6.28119440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3429E772-5697-430E-8B24-CAB4568B254A</gtr:id><gtr:title>Minor groove binders as anti-infective agents.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55ba8c0883c0b61ad823b3dffc3d6891"><gtr:id>55ba8c0883c0b61ad823b3dffc3d6891</gtr:id><gtr:otherNames>Barrett MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>56e1301805e5f9.02932234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4008B57C-EBB7-4E61-B127-D3F7A59CEECF</gtr:id><gtr:title>Thiazotropsin aggregation and its relationship to molecular recognition in the DNA minor groove.</gtr:title><gtr:parentPublicationTitle>Biophysical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52e92225234f12b3b0ac28b3134c9b2d"><gtr:id>52e92225234f12b3b0ac28b3134c9b2d</gtr:id><gtr:otherNames>Salvia MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0301-4622</gtr:issn><gtr:outcomeId>56e130d4621274.40303658</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13648E1B-0FFB-402F-A31D-5A3E4A5D7D0C</gtr:id><gtr:title>Recognition of the DNA minor groove by thiazotropsin analogues.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e4f8ae0605e3400d2c1b3ae3d5200b5"><gtr:id>2e4f8ae0605e3400d2c1b3ae3d5200b5</gtr:id><gtr:otherNames>Alniss HY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>56e1308e4ca2e1.74940018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C007FE3B-597E-4F5A-B7B5-CC48FD80DF93</gtr:id><gtr:title>Small-molecule inhibitors of I?B kinase (IKK) and IKK-related kinases.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical patent analyst</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60bcff49016a01d91aaf15f66ea09b92"><gtr:id>60bcff49016a01d91aaf15f66ea09b92</gtr:id><gtr:otherNames>Llona-Minguez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2046-8954</gtr:issn><gtr:outcomeId>56e131722fab14.27334570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97C68BA8-3418-43C5-A85B-D9A84F364101</gtr:id><gtr:title>Stereoselective synthesis of carbocyclic analogues of the nucleoside Q precursor (PreQ0).</gtr:title><gtr:parentPublicationTitle>Beilstein journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60bcff49016a01d91aaf15f66ea09b92"><gtr:id>60bcff49016a01d91aaf15f66ea09b92</gtr:id><gtr:otherNames>Llona-Minguez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1860-5397</gtr:issn><gtr:outcomeId>56e131cd9a5890.19702262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A29935B7-1F43-4913-86D9-0B644471AB88</gtr:id><gtr:title>Mast cells promote blood brain barrier breakdown and neutrophil infiltration in a mouse model of focal cerebral ischemia.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd1f73839a97a10f6c9df30816a28a60"><gtr:id>bd1f73839a97a10f6c9df30816a28a60</gtr:id><gtr:otherNames>McKittrick CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>56e12efef15497.47947516</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12023</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>